Mardepodect, a Phase 3 clinical candidate developed by Pfizer as PF-02545920 for schizophrenia and more recently repositioned for Huntington’s Disease, is a potent PDE10A inhibitor with CNS penetrant properties that may make it suitable for repositioning in GBM. Here, PDE10A is linked to schizophrenia.